Brief: Urogen Pharma Announced Final Results From Single-Arm, Open-Label OPTIMA II Phase 2B Trial Evaluating Efficacy And Safety Of Investigational UGNn--102

UroGen Pharma

17/11/2020 13:15

Nov 17 (Reuters) - Urogen Pharma Ltd  UR8.F :
    * UROGEN PHARMA - ANNOUNCED FINAL RESULTS FROM SINGLE-ARM,
OPEN-LABEL OPTIMA II PHASE 2B TRIAL EVALUATING EFFICACY AND
SAFETY OF INVESTIGATIONAL UGN-102
    * UROGEN PHARMA LTD - 65% COMPLETE RESPONSE RATE AT THREE
MONTHS
    * UROGEN PHARMA LTD - DURATION OF RESPONSE ESTIMATED TO BE
72.5%
AT NINE MONTHS (12-MONTHS FROM INITIATION OF THERAPY) BY
KAPLAN-MEIER METHOD
    * UROGEN PHARMA LTD - MEDIAN DURATION OF RESPONSE WAS NOT
REACHED
    * UROGEN PHARMA LTD - TREATMENT WITH UGN-102 WAS GENERALLY
WELL
TOLERATED, WITH MOSTLY MILD TO MODERATE ADVERSE EVENTS REPORTED
    * UROGEN PHARMA LTD - PHASE 3 PIVOTAL TRIAL EVALUATING
UGN-102
VERSUS CURRENT STANDARD OF CARE EXPECTED TO START BY YEAR-END

Source text for Eikon:  ID:nBwbp0Pb0a 
Further company coverage:  UR8.F 

 ((Reuters.Briefs@thomsonreuters.com;))